| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/17/2004 | US20040116424 Aryl imidazoles and related compounds as C5a receptor modulators |
| 06/17/2004 | US20040116423 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| 06/17/2004 | US20040116422 Drugs as enzyme inhibitors for tyrosine kinases and for treatment of psoriasis |
| 06/17/2004 | US20040116417 Thiohydantoins and use thereof for treating diabetes |
| 06/17/2004 | US20040116416 having immunomodulating and cytokine-release-inhibiting action |
| 06/17/2004 | US20040116415 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 06/17/2004 | US20040116405 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| 06/17/2004 | US20040116400 Compounds, compositions, and methods |
| 06/17/2004 | US20040116392 obtaining such microparticles using a fluid-bed granulation technique; small size of the microparticles ensures a fast and predictable emptying from the stomach and controllable plasma levels of the absorbed drug |
| 06/17/2004 | US20040116388 triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides |
| 06/17/2004 | US20040116387 thyroid receptor ligands, preferably antagonists for the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subcllinical hyperthyrodism and liver diseases |
| 06/17/2004 | US20040116374 C2, 8-disubstituted adenosine derivatives and their different uses |
| 06/17/2004 | US20040116357 For prophylaxis and therapy of hyperglycemia such as diabetes, diabetic complications or obesity |
| 06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
| 06/17/2004 | US20040116353 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 06/17/2004 | US20040116342 Therapeutic use of a SMR1-peptide or a pharmaceutically active amount of SMR1-peptide, for the preparation of a therapeutic formulation for preventing or treating diseases wherein a modulation of activity of a membrane metallopeptidase is sought |
| 06/17/2004 | US20040116336 Peptide derivatives |
| 06/17/2004 | US20040116328 Condensed imidazole derivatives |
| 06/17/2004 | US20040116327 Administering compound capable of simultaneously binding PPAR alpha and PPAR gamma or concomitantly administering a compound that selectively binds PPAR alpha with a compound that selectively binds PPAR gamma to prevent rupture |
| 06/17/2004 | US20040115808 In vitro neuronal stem cell culture for transplantation and treatment of neurodegenerative and gastrointestinal diseases; tissue engineering |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115666 Method for identifying compounds modulating reverse cholesterol transport |
| 06/17/2004 | US20040115227 Thermoformable solid pharmaceutical composition for controlled release of perindopril |
| 06/17/2004 | US20040115202 monospecific antibody which specifically binds an epitope of a mammalian DPPIV (dipeptidyl peptidase IV, also known as CD26). |
| 06/17/2004 | US20040115184 Methods and compositions for modifying apolipoprotein b mrna editing |
| 06/17/2004 | US20040115181 Composition for transmucosal adminstration containing conenzyme q as the active ingredient |
| 06/17/2004 | DE20220901U1 Film coating composition for controlled release of active ingredient e.g. metoprolol, comprises an acrylic polymer dispersion, a surfactant, sodium stearyl fumarate and a water-containing liquid |
| 06/17/2004 | CA2508329A1 Substituted dihydrophenanthridinesul fonamides |
| 06/17/2004 | CA2508319A1 Jnk inhibitors |
| 06/17/2004 | CA2507763A1 Fused 1,3-dihydro-imidazole ring compounds |
| 06/17/2004 | CA2507750A1 Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
| 06/17/2004 | CA2507534A1 Methods for treating or preventing angiogenesis-dependent symptoms |
| 06/17/2004 | CA2506741A1 Compounds with mixed pde-inhibitory and .beta.-adrenergic antagonist or partial agonist activity for treatment of heart failure |
| 06/17/2004 | CA2506630A1 Heart failure gene determination and therapeutic screening |
| 06/17/2004 | CA2503973A1 Material compositions and related systems and methods for treating cardiac conditions |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/16/2004 | EP1428877A1 Novel protein and dna thereof |
| 06/16/2004 | EP1428832A2 Peptide and O-glycan inhibitors of selectin mediated inflammation |
| 06/16/2004 | EP1428531A1 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| 06/16/2004 | EP1428529A1 Apolipo protein e secretion promoters |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427842A2 Mid 9002, a human sulfatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427732A1 Spirocyclic-6,7-dihydro-5h-pyrazolo 1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 06/16/2004 | EP1427729A1 Carbazole derivatives and their use as npy5 receptor antagonists |
| 06/16/2004 | EP1427728A1 6,7-DIHYDRO-5H-PYRAZOLO 1,2-A PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY cYTOKINES |
| 06/16/2004 | EP1427727A1 Compounds which inhibit the release of inflammatory cytokines |
| 06/16/2004 | EP1427720A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427718A1 Benzothiepine ileal bile acid transport inhibotors |
| 06/16/2004 | EP1427712A2 Dye-azide compounds for dual phototherapy |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427457A1 Medical devices containing rapamycin analogs |
| 06/16/2004 | EP1427432A2 Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427424A2 Lpa receptor agonists and antagonists and methods of use |
| 06/16/2004 | EP1427423A1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 06/16/2004 | EP1427418A2 Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment |
| 06/16/2004 | EP1427415A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| 06/16/2004 | EP1427412A1 Methods of treating cytokine mediated diseases |
| 06/16/2004 | EP1427409A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s) |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427401A2 Method for reducing hypertension and heart failure |
| 06/16/2004 | EP1351958B1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1339406B1 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/16/2004 | EP1315731B1 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| 06/16/2004 | EP1268387B1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
| 06/16/2004 | EP1235777B1 Vitamin d analogues |
| 06/16/2004 | EP1194411B1 Benzoylpyridazines |
| 06/16/2004 | EP1109810B1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
| 06/16/2004 | EP1100476B1 Formulations for the transdermal administration of fenoldopam |
| 06/16/2004 | EP0983243B1 Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
| 06/16/2004 | EP0906102B1 A process for regulating vagal tone |
| 06/16/2004 | EP0815080B1 Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
| 06/16/2004 | CN1505638A Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| 06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
| 06/16/2004 | CN1505630A Pyrazolo[1,5-a]pyridines and medicaments containing thereof |
| 06/16/2004 | CN1505628A Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505625A Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 06/16/2004 | CN1505623A Benzoaxathiepin derivatives and their use as medicines |
| 06/16/2004 | CN1505618A Dimeric isoflavones |
| 06/16/2004 | CN1505617A Peptides as met-ap2 inhibitors |
| 06/16/2004 | CN1505614A Process for making amlodipine maleate |
| 06/16/2004 | CN1505613A Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents |
| 06/16/2004 | CN1505603A Substituted benzoic ac id derivatives exhibiting nf-ª—b inhibiting activity |
| 06/16/2004 | CN1505551A Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
| 06/16/2004 | CN1505525A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 06/16/2004 | CN1505514A Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| 06/16/2004 | CN1505513A Aqueous cilostazol preparation for injection |
| 06/16/2004 | CN1505512A A stable pharmaceutical formulation comprising torsemide modification II |
| 06/16/2004 | CN1505505A Composition for administration to mucosa and containing coenzyme Q as active ingredient |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504480A Endothelin receptor antagonist of tripeptide |
| 06/16/2004 | CN1504223A Hemorrhoid treating pill with consolidation of origin |
| 06/16/2004 | CN1504221A Medicine composition for ischemia apoplexy |
| 06/16/2004 | CN1504209A Process of healthcare capsule of edible cactus |
| 06/16/2004 | CN1504208A Gingko drop pill for prevention and treatment of cardiovascular and cerebrovascular disease |